Plunkett ML - Search Results

1

Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.

Doñate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. Doñate F, et al. Among authors: plunkett ml. Clin Cancer Res. 2008 Apr 1;14(7):2137-44. doi: 10.1158/1078-0432.CCR-07-4530. Clin Cancer Res. 2008. PMID: 18381955

2

Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.

Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F. Juarez JC, et al. Among authors: plunkett ml. Cancer Res. 2002 Sep 15;62(18):5344-50. Cancer Res. 2002. PMID: 12235005

3

Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities.

Doñate F, Juarez JC, Guan X, Shipulina NV, Plunkett ML, Tel-Tsur Z, Shaw DE, Morgan WT, Mazar AP. Doñate F, et al. Among authors: plunkett ml. Cancer Res. 2004 Aug 15;64(16):5812-7. doi: 10.1158/0008-5472.CAN-04-0440. Cancer Res. 2004. PMID: 15313924

4

A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.

Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA. Khalili P, et al. Among authors: plunkett ml. Mol Cancer Ther. 2006 Sep;5(9):2271-80. doi: 10.1158/1535-7163.MCT-06-0100. Mol Cancer Ther. 2006. PMID: 16985061

5

Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Danese S, Sans M, Spencer DM, Beck I, Doñate F, Plunkett ML, de la Motte C, Redline R, Shaw DE, Levine AD, Mazar AP, Fiocchi C. Danese S, et al. Among authors: plunkett ml. Gut. 2007 Jun;56(6):855-62. doi: 10.1136/gut.2006.114314. Epub 2006 Dec 14. Gut. 2007. PMID: 17170016 Free PMC article.

6

Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides.

Zhang JC, Qi X, Juarez J, Plunkett M, Donaté F, Sakthivel R, Mazar AP, McCrae KR. Zhang JC, et al. Can J Physiol Pharmacol. 2002 Feb;80(2):85-90. doi: 10.1139/y02-011. Can J Physiol Pharmacol. 2002. PMID: 11934260

7

A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis.

Robertson NE, Discafani CM, Downs EC, Hailey JA, Sarre O, Runkle RL Jr, Popper TL, Plunkett ML. Robertson NE, et al. Among authors: plunkett ml. Cancer Res. 1991 Feb 15;51(4):1339-44. Cancer Res. 1991. PMID: 1705173

8

An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate.

Plunkett ML, Hailey JA. Plunkett ML, et al. Lab Invest. 1990 Apr;62(4):510-7. Lab Invest. 1990. PMID: 1692100

9

Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro.

Downs EC, Robertson NE, Riss TL, Plunkett ML. Downs EC, et al. Among authors: plunkett ml. J Cell Physiol. 1992 Aug;152(2):422-9. doi: 10.1002/jcp.1041520225. J Cell Physiol. 1992. PMID: 1379248

10

Epicardial and corneal mineralization in clinically normal severe combined immunodeficiency (SCID) mice.

Meador VP, Tyler RD, Plunkett ML. Meador VP, et al. Among authors: plunkett ml. Vet Pathol. 1992 May;29(3):247-9. doi: 10.1177/030098589202900309. Vet Pathol. 1992. PMID: 1621336 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters